Details for Patent: 8,088,368
✉ Email this page to a colleague
Which drugs does patent 8,088,368 protect, and when does it expire?
Patent 8,088,368 protects HARVONI and is included in two NDAs.
Protection for HARVONI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and thirty-eight patent family members in thirty-nine countries.
Summary for Patent: 8,088,368
Title: | Antiviral compounds |
Abstract: | The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. |
Inventor(s): | Guo; Hongyan (Foster City, CA), Kato; Darryl (Foster City, CA), Kirschberg; Thorsten A. (Foster City, CA), Liu; Hongtao (Foster City, CA), Link; John O. (Foster City, CA), Mitchell; Michael L. (Foster City, CA), Parrish; Jay P. (Foster City, CA), Sun; Jianyu (Foster City, CA), Taylor; James (Foster City, CA), Bacon; Elizabeth M. (Foster City, CA), Canales; Eda (Foster City, CA), Cho; Aesop (Foster City, CA), Kim; Choung U. (Foster City, CA), Cottell; Jeromy J. (Foster City, CA), Desai; Manoj C. (Foster City, CA), Halcomb; Randall L. (Foster City, CA), Lazerwith; Scott E. (Foster City, CA), Mackman; Richard L. (Foster City, CA), Pyun; Hyung-Jung (Foster City, CA), Saugier; Joseph H. (Foster City, CA), Trenkle; James D. (Foster City, CA), Tse; Winston C. (Foster City, CA), Watkins; William J. (Foster City, CA), Xu; Lianhong (Foster City, CA) |
Assignee: | Gilead Sciences, Inc. (Foster City, CA) |
Application Number: | 12/779,023 |
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 8,088,368
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-001 | Aug 28, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-002 | Aug 28, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | TABLET;ORAL | 205834-002 | Aug 28, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | TABLET;ORAL | 205834-001 | Oct 10, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,088,368
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
African Regional IP Organization (ARIPO) | 3622 | ⤷ Try a Trial | |||
Argentina | 076765 | ⤷ Try a Trial | |||
Australia | 2010249043 | ⤷ Try a Trial | |||
Brazil | 122014012810 | ⤷ Try a Trial | |||
Brazil | 122014013631 | ⤷ Try a Trial | |||
Brazil | PI1010795 | ⤷ Try a Trial | |||
Canada | 2761258 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |